Fulgent Genetics price target lowered to $50 from $65 at Credit Suisse

Credit Suisse analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics to $50 from $65 and keeps an Outperform rating on the shares following quarterly results. The analyst believes the company is poised to gain share in the genetic and oncology testing markets due to synergies from its recent acquisitions and disruptions at competitors.